LG Chem is collaborating with Chinese biotech OTR Therapeutics to discover and develop cancer drug candidates. This partnership aims to leverage China's rapid drug development capabilities alongside LG Chem's global clinical and commercialization experience to proactively secure a follow-up cancer pipeline.
On July 8, LG Chem announced it has signed a strategic collaboration agreement with OTR Therapeutics for the discovery and development of cancer drug candidates. Through this collaboration, LG Chem plans to jointly explore and evaluate promising cancer drug candidates in China and expand opportunities for licensing superior compounds.
OTR, based in Shanghai, is a biotech company with research and development capabilities in oncology, immunology, inflammatory diseases, and metabolic disorders. LG Chem will utilize OTR's network and development experience in China to conduct preclinical and early clinical trials locally, while later-stage clinical trials and commercialization will adhere to global standards.
Son Ji-woong, head of LG Chem's Life Sciences Division, stated, "We have strengthened the foundation to systematically discover and validate promising candidates, and through proactive acquisition, we aim to enhance global competitiveness and patient accessibility."
Meanwhile, LG Chem is currently conducting a global Phase 3 clinical trial for its head and neck cancer treatment candidate, 'Pyclatuzumab.' This monoclonal antibody-based targeted therapy inhibits the action of hepatocyte growth factor (HGF), which is involved in tumor growth and metastasis.
Additionally, the company has initiated Phase 1 and 2 clinical trials for 'LG00313112,' a solid tumor treatment targeting the TP53 Y220C mutation. LG00313112 was introduced through a contract with Frontier Medicines in April, granting LG Chem global exclusive development and commercialization rights, excluding Greater China (mainland China, Hong Kong, Macau, Taiwan).
LG00313112 targets the 'TP53 Y220C' mutation, which is found in 1-3% of all cancer patients. The drug works by stabilizing the structurally unstable p53 protein caused by this mutation, restoring its original tumor-suppressing function.
On July 8, LG Chem announced it has signed a strategic collaboration agreement with OTR Therapeutics for the discovery and development of cancer drug candidates. Through this collaboration, LG Chem plans to jointly explore and evaluate promising cancer drug candidates in China and expand opportunities for licensing superior compounds.
OTR, based in Shanghai, is a biotech company with research and development capabilities in oncology, immunology, inflammatory diseases, and metabolic disorders. LG Chem will utilize OTR's network and development experience in China to conduct preclinical and early clinical trials locally, while later-stage clinical trials and commercialization will adhere to global standards.
Son Ji-woong, head of LG Chem's Life Sciences Division, stated, "We have strengthened the foundation to systematically discover and validate promising candidates, and through proactive acquisition, we aim to enhance global competitiveness and patient accessibility."
Meanwhile, LG Chem is currently conducting a global Phase 3 clinical trial for its head and neck cancer treatment candidate, 'Pyclatuzumab.' This monoclonal antibody-based targeted therapy inhibits the action of hepatocyte growth factor (HGF), which is involved in tumor growth and metastasis.
Additionally, the company has initiated Phase 1 and 2 clinical trials for 'LG00313112,' a solid tumor treatment targeting the TP53 Y220C mutation. LG00313112 was introduced through a contract with Frontier Medicines in April, granting LG Chem global exclusive development and commercialization rights, excluding Greater China (mainland China, Hong Kong, Macau, Taiwan).
LG00313112 targets the 'TP53 Y220C' mutation, which is found in 1-3% of all cancer patients. The drug works by stabilizing the structurally unstable p53 protein caused by this mutation, restoring its original tumor-suppressing function.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.